Assessment of Functional and Symptom Outcomes for Survivors of Paranasal Sinus, Nasopharyngeal and Skull Base Tumors

NCT05733091 | Recruiting

• 2 other identifiers: PA18-0969NCI-2023-01436
• Study Type: observational
• Target: 300
• Locations: 1 country
• Sites: 1

Brief Summary

To learn about the symptoms and changes our patients experience while receiving treatment for sinonasal or nasopharyngeal cancer

Conditions

Tumors

Outcome Measures

Primary Outcomes (1)

• MD Anderson Symptom Inventory Head and Neck Module (MDASI-HN)

  MD Anderson Symptom Inventory Head and Neck Module (MDASI-HN) is a disease specific PRO instrument validated for patients with head and neck cancer. It is the most commonly utilized instrument in the head and neck cancer population, of which sinonasal and nasopharyngeal tumors are disease subsites. Score scale from 0 (symptom has been present) to 10 (the symptom was as bad as you can imagine it could be)

  through study completion; an average of 1 year

Interventions

Standard of Care BEHAVIORAL

Standard of care assessment of their function including pituitary hormone lab draws, audiogram hearing test, eye exam, teeth and jaw exam (in trismus clinic) and speech and swallowing evaluation

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

M D Anderson Cancer Center

You may qualify if:

• Previously untreated patients with or suspected to have sinonasal malignancy or nasopharyngeal malignancy diagnosis based on either outside pathology report or MD Anderson pathology report.
• Age ≥ 18 years
• Plan to obtain the majority of treatment at MDACC including surgery and radiotherapy
• Ability to understand and willingness to sign written informed consent

You may not qualify if:

• History of the previous solid or liquid malignancies, apart from skin cancers treated with local therapy.
• Existing neurocognitive impairment that is not the result of sinonasal and nasopharyngeal cancers or is treatment.
• Previous treatment for sinonasal or nasopharyngeal carcinomas, apart from biopsy.

Sponsors & Collaborators

• M.D. Anderson Cancer Center: lead

Study Sites (1)

M D Anderson Cancer Center

Houston, Texas, 77030, United States

RECRUITING

Related Links

• M D Anderson Cancer Center

MeSH Terms

Conditions

Neoplasms

Interventions

Standard of Care

Intervention Hierarchy (Ancestors)

Quality Indicators, Health Care; Quality of Health Care; Health Services Administration; Health Care Quality, Access, and Evaluation

Study Officials

• Shirley Su, MBBS

  M.D. Anderson Cancer Center

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Shirley Su, MBBS

CONTACT

(713) 792-4720; sysu@mdanderson.org

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 8, 2023
• First Posted: February 17, 2023
• Study Start: December 20, 2018
• Primary Completion (Estimated): December 31, 2029
• Study Completion (Estimated): December 31, 2029
• Last Updated: April 21, 2026

Record last verified: 2026-04

Locations

US (1)